subconjunctival latanoprost insert (VS-101) / BioLight Life Sci - LARVOL DELTA

BioLight reports successful results in phase 1/2a clinical trial for glaucoma insert (PipelineReview) - P1/2a, N=77; "Mean diurnal IOP before treatment of patients that were treated with the effective dosed insert and completed the trial was 23.5 mmHg. A sustained reduction in IOP was observed with average diurnal IOP 17.9 mmHg at the primary endpoint of 12 weeks (5.6 mmHg, 24% reduction)."

P1/2 data • Glaucoma • Ophthalmology

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma (Dovepress) - P=NA, N=NA; "Furthermore, BAK-free latanoprost was well tolerated with only mild-to-moderate and self-limiting AEs. BAK-free latanoprost appears to be effective in protecting ocular surface integrity in glaucoma patients but further studies are needed to confirm this beneficial effect."

Clinical data • Glaucoma • Ophthalmology